SAB BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
SAB BIOTHERAPEUTICS, INC. (SABS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 19.61 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 964.10K shares, a 3756.40% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 18.64M shares.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 14.31M shares, a 25910.55% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 3.86M shares, a 204.01% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 18.19M shares, a 648.76% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.43M shares, a 545.97% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 376.17K shares, a 87.18% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.93M shares, a 117.83% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 964.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 19.61M shares 10-Q · filed 2026-08-06 | 33.91M shares derived: sum of 3 quarters · filed 2026-08-06 | 37.78M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 18.64M shares 10-Q · filed 2026-05-12 | 32.95M shares derived: sum of 2 quarters · filed 2026-05-12 | 36.81M shares derived: sum of 3 quarters · filed 2026-05-12 | 36.84M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 14.31M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 18.17M shares derived: sum of 2 quarters · filed 2026-03-09 | 18.19M shares derived: sum of 3 quarters · filed 2026-03-09 | 18.19M shares 10-K · filed 2026-03-09 |
| 2025-09-30 | 3.86M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 3.89M shares derived: sum of 2 quarters · filed 2025-11-14 | 3.89M shares 10-Q · filed 2025-11-14 | 3.94M shares derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | 25.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 25.00K shares 10-Q · filed 2025-08-07 | 80.00K shares derived: sum of 3 quarters · filed 2025-08-07 | 1.35M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-09 | 55.00K shares derived: sum of 2 quarters · filed 2025-05-09 | 1.33M shares derived: sum of 3 quarters · filed 2025-05-09 | 1.35M shares derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | 55.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 1.33M shares derived: sum of 2 quarters · filed 2025-03-31 | 1.35M shares derived: sum of 3 quarters · filed 2025-03-31 | 2.43M shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 1.27M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 1.29M shares derived: sum of 2 quarters · filed 2024-11-06 | 2.37M shares 10-Q · filed 2024-11-06 | -160.62K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 20.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 1.10M shares 10-Q · filed 2024-08-08 | -1.43M shares derived: sum of 3 quarters · filed 2024-08-08 | -1.43M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-03-31 | 1.08M shares 10-Q · filed 2024-05-20 | -1.45M shares derived: sum of 2 quarters · filed 2024-05-20 | -1.45M shares derived: sum of 3 quarters · filed 2024-11-06 | -1.09M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-12-31 | -2.54M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -2.54M shares derived: sum of 2 quarters · filed 2024-11-06 | -2.17M shares derived: sum of 3 quarters · filed 2024-11-06 | 376.17K shares 10-K · filed 2024-03-29 |
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-06 | 365.00K shares derived: sum of 2 quarters · filed 2024-11-06 | 2.91M shares 10-Q · filed 2023-11-13 | 2.91M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | 365.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | 2.91M shares 10-Q · filed 2023-08-21 | 2.91M shares derived: sum of 3 quarters · filed 2023-08-21 | 5.32M shares derived: sum of 4 quarters · filed 2023-08-21 |
| 2023-03-31 | 2.55M shares 10-Q · filed 2023-05-15 | 2.55M shares derived: sum of 2 quarters · filed 2023-05-15 | 4.95M shares derived: sum of 3 quarters · filed 2023-05-15 | 4.99M shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-14 | 2.41M shares derived: sum of 2 quarters · filed 2023-04-14 | 2.45M shares derived: sum of 3 quarters · filed 2023-04-14 | 2.93M shares 10-K · filed 2023-04-14 |
| 2022-09-30 | 2.41M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 2.45M shares derived: sum of 2 quarters · filed 2022-11-14 | 2.93M shares 10-Q · filed 2022-11-14 | |
| 2022-06-30 | 41.28K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 528.71K shares 10-Q · filed 2022-08-10 | ||
| 2022-03-31 | 487.43K shares 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 1.35M shares 10-K/A · filed 2023-04-28 | |||
| 2021-09-30 | 0.00 shares 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | 962.09K shares 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |